A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

Inclusion Criteria:

* Histologically documented locally advanced or metastatic solid tumor that has progressed or failed to respond to at least one prior regimen.
* Not a candidate for regimens known to provide clinical benefit.
* Evaluable or measurable disease according to RECIST, v1.1.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
* Life expectancy of \>= 12 weeks.
* Adequate haematologic and organ function within 14 days prior to initiation of study treatment.
* Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating eggs.
* Men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.
* Participants must reside in the People's Republic of China

Exclusion Criteria:

* Leptomeningeal disease as the only manifestation of the current tumor.
* Type 1 or 2 diabetes mellitus requiring insulin at study entry.
* Inability or unwillingness to swallow pills.
* Malabsorption syndrome or other condition that would interfere with enteral absorption.
* Known and untreated, or active CNS metastases (progressing or requiring anticonvulsants for symptomatic control).
* Congenital long QT syndrome or corrected QT interval (QTc) \> 480 ms.
* Active congestive heart failure or ventricular arrhythmia requiring medication.
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring weekly paracentesis for 3 consecutive weeks prior to initiation of ipatasertib treatment.
* Severe infections within 4 weeks prior to screening including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
* Requirement for any daily supplemental oxygen.
* History of Inflammatory bowel disease or active bowel inflammation.
* Symptomatic hypercalcemia requiring continued use of bisphosphonate or denosumab therapy.
* Clinically significant history of liver disease, including viral disease or hepatitis,current alcohol abuse or cirrhosis.
* Known HIV infection.
* Active (chronic or acute) hepatitis C virus (HCV) at screening.
* Hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test or a positive quantitative HBV DNA test at screening
* Significant traumatic injury within 3 weeks prior to initiation of ipatasertib treatment.
* Major surgical procedure within 4 weeks prior to initiation of ipatasertib treatment.
* Treatment with chemotherapy, immunotherapy, or biologic therapy as cancer therapy within 3 weeks prior to initiation of ipatasertib treatment.
* Use of strong CYP3A4 inhibitors within 4 weeks prior to initiation of ipatasertib treatment.
* Oral endocrine therapy within 2 weeks prior to initiation of ipatasertib treatment.
* Prior treatment with a PI3-kinase inhibitor in which the patient experienced a Grade \>= 3 drug-related adverse event or otherwise would be at increased risk for additional PI3K-related toxicity.
* Palliative radiation to bony metastases within 2 weeks prior to initiation of ipatasertib treatment.
* Radiotherapy (other than palliative radiation to bony metastases) as cancer therapy within 4 weeks prior to initiation of ipatasertib treatment.
* Treatment with an investigational agent within 4 weeks prior to initiation of ipatasertib treatment.
* Unresolved toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathy.
* Pregnant or lactating.
* Inability to comply with study and follow-up procedures.